Academic Journals Database
Disseminating quality controlled scientific knowledge

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

Author(s): Joan Khoo | Christopher K Rayner | Karen L Jones | et al

Journal: Therapeutics and Clinical Risk Management
ISSN 1176-6336

Volume: 2009;
Issue: default;
Start page: 683;
Date: 2009;
Original page

Joan Khoo, Christopher K Rayner, Karen L Jones, Michael HorowitzDiscipline of Medicine, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaAbstract: The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term.Keywords: incretin, type 2 diabetes, therapy, GLP-1, DPP-4
Affiliate Program     

Tango Rapperswil
Tango Rapperswil